Abstract
This chapter provides an introduction to proteomics and describes current applications of proteomic technologies in investigative and clinical settings. Mass spectrometry-based proteomics is emphasized as a technology for unbiased and targeted interrogation of complex protein mixtures. Technological advances now permit higher sensitivity and accuracy for detection and quantification of biomarkers. Perspectives on current and future applications of mass spectrometry-based proteomics are provided in the context of diagnostic laboratory testing.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bauer JA, Chakravarthy AB, et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res. 2010;16(2):681–90.
Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355–65.
Conlon KP, Basrur V, et al. Fusion peptides from oncogenic chimeric proteins as putative specific biomarkers of cancer. Mol Cell Proteomics. 2013.
Druker BJ, Guilhot F, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–17.
Fenn JB, Mann M, et al. Electrospray ionization for mass spectrometry of large biomolecules. Science. 1989;246(4926):64–71.
Figueroa JJ, Peter Bosch E, et al. Amyloid-like IgM deposition neuropathy: a distinct clinico-pathologic and proteomic profiled disorder. J Peripher Nerv Syst. 2012;17(2):182–90.
Flatley B, Malone P, et al. MALDI mass spectrometry in prostate cancer biomarker discovery. Biochim Biophys Acta. 2013. pii: S1570-9639(13)00252–5.
Fortin T, Salvador A, et al. Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol Cell Proteomics. 2009;8(5):1006–15.
Groseclose MR, Massion PP, et al. High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics. 2008;8(18):3715–24.
Hunter T. Signaling—2000 and beyond. Cell. 2000;100(1):113–27.
Karas M, Bachamann D, et al. Matrix-assisted ultraviolet laser desorption of non-volatile compounds. Int J Mass Spectrom Ion Proc. 1989;78:53–68.
Kuhn E, Wu J, et al. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics. 2004;4(4):1175–86.
Lange V, Picotti P, et al. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol. 2008;4:222.
Larsen MR, Thingholm TE, et al. Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol Cell Proteomics. 2005;4(7):873–86.
Matsuo K, Arito M, et al. Arthritogenicity of annexin VII revealed by phosphoproteomics of rheumatoid synoviocytes. Ann Rheum Dis. 2011;70(8):1489–95.
Olsen JV, Ong SE, et al. Trypsin cleaves exclusively C-terminal to arginine and lysine residues. Mol Cell Proteomics. 2004;3(6):608–14.
Oppenheimer SR, Mi D, et al. Molecular analysis of tumor margins by MALDI mass spectrometry in renal carcinoma. J Proteome Res. 2010;9(5):2182–90.
Rauser S, Marquardt C, et al. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res. 2010;9(4):1854–63.
Rush J, Moritz A, et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol. 2005;23(1):94–101.
Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211–25.
Schwamborn K, Krieg RC, et al. Identifying prostate carcinoma by MALDI-Imaging. Int J Mol Med. 2007;20(2):155–9.
Stoeckli M, Chaurand P, et al. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med. 2001;7(4):493–6.
Tanaka K, Waki H, et al. Protein and polymer analysis up to m/z 100 000 by ionization time-flight mass spectrometry. Rapid Commun Mass Spectrom. 1988;2(151–2).
van den Broek I, Sparidans RW, et al. Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(5–6):590–602.
Vrana JA, Gamez JD, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957–9.
Wang Q, Chaerkady R, et al. Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci U S A. 2011;A108(6):2444–9.
Zahedi RP, Lewandrowski U, et al. Phosphoproteome of resting human platelets. J Proteome Res. 2008;7(2):526–34.
Zhang H, Li XJ, et al. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003;21(6):660–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Conlon, K.P., Rolland, D., Elenitoba-Johnson, K.S.J. (2014). Proteomics in Cancer Diagnostics. In: Yousef, G., Jothy, S. (eds) Molecular Testing in Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4899-8050-2_8
Download citation
DOI: https://doi.org/10.1007/978-1-4899-8050-2_8
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4899-8049-6
Online ISBN: 978-1-4899-8050-2
eBook Packages: MedicineMedicine (R0)